Celldex Therapeutics (CLDX) Income from Continuing Operations (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Income from Continuing Operations of 85903000.0 for Q1 2026, down 37.12% year-over-year from 136604892.5 in Q1 2025, and up 21.63% quarter-over-quarter from 109619000.0 in Q4 2025.
Powered by 
Analysis
Celldex Therapeutics (CLDX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 85903000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 37.12% year-over-year to 85903000.0; the TTM figure through Mar 2026 stood at 326773000.0 (up 34.59% YoY), while the FY2025 annual figure was 661560000.0, down 38.51% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 85903000.0, up from 109619000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 23050000.0 in Q1 2022, with the low at 390692000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 47734000.0 (2024), against an average of 87009235.29.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slumped 1375.03% in 2023, then jumped 67.81% in 2025.
- Celldex Therapeutics' Income from Continuing Operations stood at 26487000.0 in 2022, then plunged by 1375.03% to 390692000.0 in 2023, then increased by 12.83% to 340548000.0 in 2024, then surged by 67.81% to 109619000.0 in 2025, then grew by 21.63% to 85903000.0 in 2026.
- Business Quant data shows CLDX's Income from Continuing Operations at 85903000.0 in Q1 2026, 109619000.0 in Q4 2025, and 67047000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Celldex Therapeutics | 3.07 Bn | 3.07 Bn | -2.57 Mn | -73.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -73.50 Mn |
| Mar 31, 2026 | -85.54 Mn |
| Dec 31, 2025 | -81.32 Mn |
| Sep 30, 2025 | -67.04 Mn |
| Jun 30, 2025 | -56.60 Mn |
| Mar 31, 2025 | -62.49 Mn |
| Dec 31, 2024 | -47.09 Mn |
| Sep 30, 2024 | -42.12 Mn |
| Jun 30, 2024 | -46.78 Mn |
| Mar 31, 2024 | -41.67 Mn |
| Dec 31, 2023 | -43.31 Mn |
| Sep 30, 2023 | -38.26 Mn |
| Jun 30, 2023 | -33.26 Mn |
| Mar 31, 2023 | -31.61 Mn |
| Dec 31, 2022 | -26.49 Mn |
| Sep 30, 2022 | -26.78 Mn |
| Jun 30, 2022 | -36.00 Mn |
| Mar 31, 2022 | -23.05 Mn |
| Dec 31, 2021 | -5.52 Mn |
| Sep 30, 2021 | -20.45 Mn |